Preliminary safety evaluation of a taurocholate-conjugated low-molecular-weight heparin derivative (LHT7): a potent angiogenesis inhibitor.

about

Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms.Safety studies on intravenous infusion of a potent angiogenesis inhibitor: taurocholate-conjugated low molecular weight heparin derivative LHT7 in preclinical models.

P2860

Q38749053-CB887F20-E29D-480A-B4E9-46FBF78DBADB Q47344298-B8058D60-7914-4565-B21B-35447C428641

P2860

Preliminary safety evaluation of a taurocholate-conjugated low-molecular-weight heparin derivative (LHT7): a potent angiogenesis inhibitor.

Item

http://www.wikidata.org/entity/Q38441344

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Preliminary safety evaluation ...... potent angiogenesis inhibitor.

@en

type

Item

label

Preliminary safety evaluation ...... potent angiogenesis inhibitor.

@en

prefLabel

Preliminary safety evaluation ...... potent angiogenesis inhibitor.

@en

P1476

Preliminary safety evaluation ...... potent angiogenesis inhibitor.

@en

P2093

Farzana Alam

http://www.w3.org/2001/XMLSchema#string

Hyun Tae Moon

http://www.w3.org/2001/XMLSchema#string

Ji-Young Kim

http://www.w3.org/2001/XMLSchema#string

Jooho Park

http://www.w3.org/2001/XMLSchema#string

Seung Rim Hwang

http://www.w3.org/2001/XMLSchema#string

Seung Woo Chung

http://www.w3.org/2001/XMLSchema#string

Youngro Byun

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor angiogenesis: therapeutic implications

Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src.

Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer.

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies

Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer

Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats.

Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor.

Isolation of a tumor factor responsible for angiogenesis.

Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules.

Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.

P304

104-115

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JAT.2995

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260213218

http://www.w3.org/2001/XMLSchema#string

P698

24532548

http://www.w3.org/2001/XMLSchema#string

Preliminary safety evaluation of a taurocholate-conjugated low-molecular-weight heparin derivative (LHT7): a potent angiogenesis inhibitor.

about

P2860

P2860

Preliminary safety evaluation of a taurocholate-conjugated low-molecular-weight heparin derivative (LHT7): a potent angiogenesis inhibitor.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698